BR112022024484A2 - Terapias contra o câncer com o inibidor seletivo de cdk4/6 - Google Patents
Terapias contra o câncer com o inibidor seletivo de cdk4/6Info
- Publication number
- BR112022024484A2 BR112022024484A2 BR112022024484A BR112022024484A BR112022024484A2 BR 112022024484 A2 BR112022024484 A2 BR 112022024484A2 BR 112022024484 A BR112022024484 A BR 112022024484A BR 112022024484 A BR112022024484 A BR 112022024484A BR 112022024484 A2 BR112022024484 A2 BR 112022024484A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- compounds
- inhibitors
- therapies
- cancer therapies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
TERAPIAS CONTRA O CÂNCER COM O INIBIDOR SELETIVO DE CDK4/6. A presente invenção refere-se a modalidades de inibidores potentes e seletivos de CDK 4/6 que apresentam uma inibição vantajosa do crescimento do câncer, mesmo em baixas concentrações. Conforme aqui descrito, os compostos da presente abordagem compreendem compostos piridinilpiperazina-pirrolopirimidina substituídos com uma porção de ácido graxo. Os compostos descritos podem ser utilizados como compostos farmacêuticos para terapias de combate ao câncer, e são úteis para o tratamento, a prevenção e/ou a melhora do câncer. Fórmula (a):
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037898P | 2020-06-11 | 2020-06-11 | |
| PCT/IB2021/055124 WO2021250614A1 (en) | 2020-06-11 | 2021-06-10 | Selective cdk4/6 inhibitor cancer therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024484A2 true BR112022024484A2 (pt) | 2022-12-27 |
Family
ID=78847036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024484A BR112022024484A2 (pt) | 2020-06-11 | 2021-06-10 | Terapias contra o câncer com o inibidor seletivo de cdk4/6 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11964983B2 (pt) |
| EP (1) | EP4165046A1 (pt) |
| JP (1) | JP2023530096A (pt) |
| KR (1) | KR20230023661A (pt) |
| CN (1) | CN115698015A (pt) |
| AU (1) | AU2021287380A1 (pt) |
| BR (1) | BR112022024484A2 (pt) |
| CA (1) | CA3185467A1 (pt) |
| IL (1) | IL298568A (pt) |
| MX (1) | MX2022015567A (pt) |
| WO (1) | WO2021250614A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434149B (zh) * | 2013-03-15 | 2021-05-28 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
| CA3152117A1 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| AU2017370694A1 (en) * | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| EP3836916A1 (en) * | 2018-08-16 | 2021-06-23 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators to treat medical disorders |
-
2021
- 2021-06-10 EP EP21821730.5A patent/EP4165046A1/en active Pending
- 2021-06-10 AU AU2021287380A patent/AU2021287380A1/en active Pending
- 2021-06-10 JP JP2022576082A patent/JP2023530096A/ja active Pending
- 2021-06-10 WO PCT/IB2021/055124 patent/WO2021250614A1/en unknown
- 2021-06-10 BR BR112022024484A patent/BR112022024484A2/pt unknown
- 2021-06-10 KR KR1020227044245A patent/KR20230023661A/ko active Search and Examination
- 2021-06-10 US US18/008,636 patent/US11964983B2/en active Active
- 2021-06-10 IL IL298568A patent/IL298568A/en unknown
- 2021-06-10 CN CN202180039343.7A patent/CN115698015A/zh active Pending
- 2021-06-10 CA CA3185467A patent/CA3185467A1/en active Pending
- 2021-06-10 MX MX2022015567A patent/MX2022015567A/es unknown
-
2023
- 2023-12-15 US US18/541,733 patent/US20240116942A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4165046A1 (en) | 2023-04-19 |
| KR20230023661A (ko) | 2023-02-17 |
| US20240116942A1 (en) | 2024-04-11 |
| US11964983B2 (en) | 2024-04-23 |
| MX2022015567A (es) | 2023-01-19 |
| CA3185467A1 (en) | 2021-12-16 |
| WO2021250614A1 (en) | 2021-12-16 |
| US20230227461A1 (en) | 2023-07-20 |
| CN115698015A (zh) | 2023-02-03 |
| JP2023530096A (ja) | 2023-07-13 |
| IL298568A (en) | 2023-01-01 |
| AU2021287380A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| BR112018075992A2 (pt) | piridinas substituídas como inibidores da dnmt1 | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| CO2023013356A2 (es) | Compuestos para la inhibición de nlrp3 y usos de estos | |
| BR112014026643A8 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112022002520A2 (pt) | Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer | |
| BR112022023271A2 (pt) | Compostos | |
| BR112022020776A2 (pt) | Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3 | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| BR112022020291A2 (pt) | Inibidores de cd38 | |
| CO2023017082A2 (es) | Compuestos de tiadiazolilo unidos a un átomo de oxígeno como inhibidores de dna polimerasa θ | |
| BR112017006425B8 (pt) | Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos | |
| BR112022024156A2 (pt) | Compostos heterocílicos antelmínticos | |
| BR112022010441A2 (pt) | Análogos de equinocandina e método de preparação para os mesmos | |
| BR112022025147A2 (pt) | Derivados de 4-etinilpiridina úteis como inibidores de gnc2 | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112023015425A2 (pt) | Derivados de uracila como inibidores de trpa1 | |
| BR112022024484A2 (pt) | Terapias contra o câncer com o inibidor seletivo de cdk4/6 | |
| BR112022015792A2 (pt) | Inibidores de pad4 heterocíclicos | |
| BR112023017040A2 (pt) | Derivados de indolina como inibidores de ddr1 e ddr2 |